All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1000+ biotech and pharma professionals? Let’s chat. 👍

*Quick note: I’m at Meeting on the Mesa this week so there’s a chance Tuesday and Wednesday’s TLDR Biotech newsletters might be delayed - apologies in advance if this happens!

THE GOOD
Approvals & Labels

Telix Pharmaceuticals’ Illuccix radiopharmaceutical nabs Health Canada label expansion
Radiopharma, imaging tracer, prostate cancer - Read more

Exact Sciences’ next-gen at-home colorectal cancer screening kit lands FDA approval
Cancer screening, diagnostics, colorectal cancer - Read more

Abbott’s mpox test handed WHO Emergency Use Listing
Diagnostics, monkeypox (mpox), infectious disease screening - Read more

THE GOOD
Business Development

Recordati pays Sanofi $875M upfront (+ $250M potential in royalties) for rare disease mAb Enjaymo
Monoclonal antibody, cold agglutinin disease, anemia - Read more

Editas Medicine to divert “up to 100%” of their Cas9 annual licensing fees (+ “mid-double-digit percentage” of their $50M contingent payment) that they receive from Vertex Pharmaceuticals to DRI Healthcare, DRI to pay Editas $57M upfront
Gene-editing, sickle cell disease, transfusion-dependent beta thalassemia - Read more 

Sanofi, GSK, CSL land (in-total) $72M in US gov contracts for bird flu vaccine production
Vaccine, bird flu (avian flu), infectious disease - Read more

THE GOOD
Clinical Trials

Biodexa Pharmaceuticals reports promising Ph1 survival data for MTX110 in recurrent glioblastoma
Small molecule nanoparticle formulation, recurrent glioblastoma, brain cancer - Read more

Ultragenyx ups the UX701 ante (dosage) in a new cohort after 6/15 patients completely tapered off standard-of-care chelators/zinc therapy
Gene therapy, Wilson disease, hepatolenticular degeneration - Read more

THE GOOD
Fundraises

Sirnaomics lands subscription share agreement, gross proceeds HKD58.9M ($7.6M)
RNA, anticoagulant disorder, cancer - Read more

PRESENTED BY YOU?
Get 1000+ sets of biotech/pharma eyeballs on your product or service 👀

Looking to promote your biotech/pharma/life science-focused product or service to a captivated audience of industry professionals?

Consider sponsoring TLDR Biotech - your sponsored feature would go right here!

Want to take the next step (or just learn more)? Just reply to this email or message me on LinkedIn.

⬇️ The Good News (Cont’d) ⬇️

THE GOOD
Investments

Chiesi Group touts operational launch of €400M ($439M) “biotech centre of excellence”
Monoclonal antibody, proteins, manufacturing - Read more

THE GOOD
Lawsuits

Alnylam Pharmaceuticals drops lawsuit against Moderna claiming COVID-19 vaccine tech delivery infringement
Vaccine, COVID-19, drug delivery, patent law - Read more [Paywall]

THE GOOD
Market Reports

Things are (mostly) perking up for biotech in Q3
Biotech investing, industry vibes - Read more [Read more]

THE GOOD
Partnerships

Amyris, Biopharmaceutical Manufacturing Preparedness Consortium partner on building US domestic drug supply resilience
Small molecule, drug supply, pharmaceutical manufacturing - Read more

Four big US cancer centres and the who’s who of AI (including Amazon, Microsoft, and Nvidia) partner to leverage AI and collective cancer data to identify trends, new treatments
AI-enabled drug discovery, cancer - Read more

THE GOOD
Product Launches

BeiGene begins US launch of Tevimbra, sets 10% discount compared to Merck & Co.’s Keytruda
Monoclonal antibody, esophageal squamous cell carcinoma, cancer - Read more

THE GOOD
Research

mRNA vaccine protects mice from dying from C. diff infections, also from recurring infections
mRNA vaccine, Clostridioides difficile (C. diff) infection - Read more

THE GOOD
Strategic Plans

Oncolytics Biotech bullish on breast cancer combo med, planning larger Ph2 to support accelerated approval bid
Oncolytic virus, small molecule, breast cancer - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Earnings & Finances

AbbVie needs to make $82M milestone payment related to “acquired in-process research & development”, resulting in lowered full-year earnings guidance
Research & development - Read more

Activist investor Starboard Value takes $1B stake in Pfizer (with backing from former Pfizer CEO & CFO), pushing for change amidst dismal recent performance
Drug development activity investor - Read more

THE BAD
Lawsuits

Texas accuses big pharmas Eli Lilly, Novo Nordisk, Sanofi and PBMs Optum Rx, Express Scripts, CVS Caremark of a “disturbing [insulin price] conspiracy”
Insulin, diabetes, drug pricing - Read more

THE BAD
Public Health

US population’s RSV vaccine uptake slower than expected this year 
Vaccine, respiratory syncytial virus (RSV), infectious disease - Read more [Paywall]

Bavarian Nordic’s mpox shot Jynneos exhibits tapering antibody activity after 6 to 12 months, though insufficient evidence for this also correlating with waning protection; study
Vaccine, monkeypox (mpox), infectious disease - Read more

THE BAD
Strategic Plans

Johnson & Johnson discontinues dengue fever prevention hopeful mosnodenvir, latest step in their purported inching away from infectious disease
Small molecule, dengue fever, infectious disease - Read more

THE UGLY
Regulatory

EMA puts finasteride and dutasteride (both alopecia & enlarged prostrate treatments) under the microscope over purported “suicidal ideation and behaviour” risks
Small molecule, androgenic alopecia, enlarged prostrate, suicidal ideation - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here